These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30268015)

  • 1. Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis.
    Prieri M; Frita R; Probst N; Sournia-Saquet A; Bourotte M; Déprez B; Baulard AR; Willand N
    Eur J Med Chem; 2018 Nov; 159():35-46. PubMed ID: 30268015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors.
    Flipo M; Desroses M; Lecat-Guillet N; Dirié B; Carette X; Leroux F; Piveteau C; Demirkaya F; Lens Z; Rucktooa P; Villeret V; Christophe T; Jeon HK; Locht C; Brodin P; Déprez B; Baulard AR; Willand N
    J Med Chem; 2011 Apr; 54(8):2994-3010. PubMed ID: 21417236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors.
    Flipo M; Desroses M; Lecat-Guillet N; Villemagne B; Blondiaux N; Leroux F; Piveteau C; Mathys V; Flament MP; Siepmann J; Villeret V; Wohlkönig A; Wintjens R; Soror SH; Christophe T; Jeon HK; Locht C; Brodin P; Déprez B; Baulard AR; Willand N
    J Med Chem; 2012 Jan; 55(1):68-83. PubMed ID: 22098589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment-Based Optimized EthR Inhibitors with
    Villemagne B; Machelart A; Tran NC; Flipo M; Moune M; Leroux F; Piveteau C; Wohlkönig A; Wintjens R; Li X; Gref R; Brodin P; Deprez B; Baulard AR; Willand N
    ACS Infect Dis; 2020 Mar; 6(3):366-378. PubMed ID: 32011115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baeyer-Villiger Monooxygenases EthA and MymA Are Required for Activation of Replicating and Non-replicating Mycobacterium tuberculosis Inhibitors.
    Grant SS; Wellington S; Kawate T; Desjardins CA; Silvis MR; Wivagg C; Thompson M; Gordon K; Kazyanskaya E; Nietupski R; Haseley N; Iwase N; Earl AM; Fitzgerald M; Hung DT
    Cell Chem Biol; 2016 Jun; 23(6):666-77. PubMed ID: 27321573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and docking studies of potent ethionamide boosters.
    Tatum NJ; Villemagne B; Willand N; Deprez B; Liebeschuetz JW; Baulard AR; Pohl E
    Acta Crystallogr C; 2013 Nov; 69(Pt 11):1243-50. PubMed ID: 24192167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
    Choi J; Park SJ; Jee JG
    Eur J Med Chem; 2015 Dec; 106():157-66. PubMed ID: 26544630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays.
    Nikiforov PO; Blaszczyk M; Surade S; Boshoff HI; Sajid A; Delorme V; Deboosere N; Brodin P; Baulard AR; Barry CE; Blundell TL; Abell C
    ACS Chem Biol; 2017 May; 12(5):1390-1396. PubMed ID: 28314097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator.
    Engohang-Ndong J; Baillat D; Aumercier M; Bellefontaine F; Besra GS; Locht C; Baulard AR
    Mol Microbiol; 2004 Jan; 51(1):175-88. PubMed ID: 14651620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis.
    Flipo M; Willand N; Lecat-Guillet N; Hounsou C; Desroses M; Leroux F; Lens Z; Villeret V; Wohlkönig A; Wintjens R; Christophe T; Kyoung Jeon H; Locht C; Brodin P; Baulard AR; Déprez B
    J Med Chem; 2012 Jul; 55(14):6391-402. PubMed ID: 22738293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-benzylsalicylthioamides: highly active potential antituberculotics.
    Dolezal R; Waisser K; Petrlíková E; Kunes J; Kubicová L; Machácek M; Kaustová J; Dahse HM
    Arch Pharm (Weinheim); 2009 Feb; 342(2):113-9. PubMed ID: 19137534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversion of antibiotic resistance in
    Blondiaux N; Moune M; Desroses M; Frita R; Flipo M; Mathys V; Soetaert K; Kiass M; Delorme V; Djaout K; Trebosc V; Kemmer C; Wintjens R; Wohlkönig A; Antoine R; Huot L; Hot D; Coscolla M; Feldmann J; Gagneux S; Locht C; Brodin P; Gitzinger M; Déprez B; Willand N; Baulard AR
    Science; 2017 Mar; 355(6330):1206-1211. PubMed ID: 28302858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethionamide biomimetic activation and an unprecedented mechanism for its conversion into active and non-active metabolites.
    Laborde J; Deraeve C; Duhayon C; Pratviel G; Bernardes-Génisson V
    Org Biomol Chem; 2016 Sep; 14(37):8848-8858. PubMed ID: 27714216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New ethionamide boosters and EthR2: structural and energetic analysis.
    Vianna JF; Bezerra KS; Lima Costa AH; Barbosa ED; Lima Neto JX; Oliveira JIN; Freire VN; Fulco UL
    Phys Chem Chem Phys; 2021 Oct; 23(40):23233-23241. PubMed ID: 34623361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The small-molecule SMARt751 reverses
    Flipo M; Frita R; Bourotte M; Martínez-Martínez MS; Boesche M; Boyle GW; Derimanov G; Drewes G; Gamallo P; Ghidelli-Disse S; Gresham S; Jiménez E; de Mercado J; Pérez-Herrán E; Porras-De Francisco E; Rullas J; Casado P; Leroux F; Piveteau C; Kiass M; Mathys V; Soetaert K; Megalizzi V; Tanina A; Wintjens R; Antoine R; Brodin P; Delorme V; Moune M; Djaout K; Slupek S; Kemmer C; Gitzinger M; Ballell L; Mendoza-Losana A; Lociuro S; Deprez B; Barros-Aguirre D; Remuiñán MJ; Willand N; Baulard AR
    Sci Transl Med; 2022 May; 14(643):eaaz6280. PubMed ID: 35507672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters.
    Nikiforov PO; Surade S; Blaszczyk M; Delorme V; Brodin P; Baulard AR; Blundell TL; Abell C
    Org Biomol Chem; 2016 Feb; 14(7):2318-26. PubMed ID: 26806381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and molecular docking studies of imidazole and benzimidazole linked ethionamide derivatives as inhibitors of InhA and antituberculosis agents.
    Raghu MS; Pradeep Kumar CB; Yogesh Kumar K; Prashanth MK; Alshahrani MY; Ahmad I; Jain R
    Bioorg Med Chem Lett; 2022 Mar; 60():128604. PubMed ID: 35123004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacterial Genome-Wide Association Identifies Novel Factors That Contribute to Ethionamide and Prothionamide Susceptibility in Mycobacterium tuberculosis.
    Hicks ND; Carey AF; Yang J; Zhao Y; Fortune SM
    mBio; 2019 Apr; 10(2):. PubMed ID: 31015328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis.
    DeBarber AE; Mdluli K; Bosman M; Bekker LG; Barry CE
    Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9677-82. PubMed ID: 10944230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural analysis of the interaction between spiroisoxazoline SMARt-420 and the Mycobacterium tuberculosis repressor EthR2.
    Wohlkönig A; Remaut H; Moune M; Tanina A; Meyer F; Desroses M; Steyaert J; Willand N; Baulard AR; Wintjens R
    Biochem Biophys Res Commun; 2017 May; 487(2):403-408. PubMed ID: 28416386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.